This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Dial Hewlett, Jr, MD; David L. Horn, MD; Celia Alfalla, MD
Lincoln Medical and Mental Health Center Bronx, NY

JAMA. 1995;273(12):916-917.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—Pyrazinamide, in combination with isoniazid and rifampin, often plays a prominent role in the therapy of tuberculosis.¹ Frequently, pyrazinamide susceptibility testing is performed, and the results generally dictate if pyrazinamide will or will not be used as a component of treatment of or prophylaxis for drug-resistant tuberculosis. Recently, our institution had a nosocomial outbreak of drug-resistant tuberculosis. When identically paired isolates were sent to two reference laboratories, however, discordant pyrazinamide susceptibility results were reported.

From 1991 to 1993, a total of 55 patients with tuberculosis resistant to rifampin, isoniazid, streptomycin sulfate, and ethambutol hydrochloride were identified by our institution.² Ten identically paired isolates of Mycobacterium tuberculosis from 10 different patients were sent to two reference laboratories for susceptibility testing. Restriction fragment length polymorphism (RFLP) analyses were performed by the Centers for Disease Control and Prevention (CDC), the Public Health Research Institute, and/or the Albert Einstein . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?